ArticleCancers2025
Trends in Survival and Mortality of "Early" Metastatic Breast Cancer in Northern Italy Following the Introduction of Targeted Therapies.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND/
objectivesIn high-income settings, the incidence of metastatic breast cancer (MBC) at diagnosis has declined, reflecting the impact of effective screening and therapeutic advances. This study examined long-term trends in MBC incidence, mortality, and survival in a province of North Italy, an area characterized by high screening participation and broad access to modern systemic treatments.
methodsAll invasive breast cancer cases (n = 10,966) diagnosed between 2000 and 2022 were retrieved from the Reggio Emilia Cancer Registry (population: 532,000). Metastatic cases were defined "early" if distant metastases occurred within six months of diagnosis. Mortality trends were assessed using joinpoint regression to estimate annual percentage changes (APCs). One-, three-, and five-year survival probabilities were calculated, with follow-up through December 2024.
resultsOverall, 511 cases (4.7%) were "early" metastatic breast cancers at diagnosis. This proportion declined from 6.4% in 2000-2003 to 3.8% in 2019-2022. One-year mortality decreased from 38.4% to 26.7% (APC = -6.6; 95% CI -13.1 to -0.5), and two-year mortality from 54.5% to 34.9% (APC = -7.3; 95% CI -12.3 to -1.4) after 2017. One- and three-year survival increased from 63% to 66% and from 39% to 42%, respectively, while five-year survival improved from 21% to 30%.
conclusionsOver more than two decades, the incidence of MBC at diagnosis and early mortality both declined, accompanied by improved survival. These trends temporally coincide with the widespread adoption of targeted therapies and sustained high screening coverage, suggesting a possible combined contribution of early detection and advances in precision medicine to the observed outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.